Subscribe

SynBiotic SE (SBX.DE)

EUR1.19 -0.04 (-3.25%)
DE XETRA Healthcare Drug Manufacturers - Specialty & Generic
Address Innere Wiener Str. 14 81667
Munich, DE
CEO Daniel Kruse
Website synbiotic.com
IPO 2021-01-07
ISIN DE000A3E5A59

Explore sections of this company profile

Description

SynBiotic SE is dedicated to pioneering cannabinoid-based pharmaceuticals and readily available health and wellness items. Its primary strategic pillars include the laboratory synthesis of cannabinoids, advanced drug discovery, the formulation of dietary aids, and the creation of cosmetic solutions. Formerly operating as Ledgertech SE, the company is headquartered in Munich, Germany.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR1.19 -0.04 (-3.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.1K
Beta
0.67
Float Shares
2.57M
Free Float %
54.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+7.04% -0.34% +3.83% -29.80% -15.00% -31.73% -46.32% -55.54% -91.57% -91.90% -91.90%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.19
Quality scores
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -52.7% Q2'24: -99.9% (vs Q4'20)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +62.0% ★ Q2'24: +55.2% (vs Q4'20)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -251.3% Q2'24: +0.0% (vs Q4'20)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -302.4% Q2'24: -18,403.2% (vs Q4'20)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -68.9% Q2'24: -5.3% (vs Q4'20)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +14.9% Q2'24: +95.6% (vs Q4'20)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -0.35× Q2'24: -1.29× (vs Q4'20)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.17) × ERP
WACC = 69% × Ke + 31% × Kd (5.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.19
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana.
Revenue
8.17M
est: 8.17M (+0.0%)
3.86M
est: 3.86M (+0.0%)
15.80M
est.
16.40M
est.
19.05M
19.05M – 19.05M
+16.2% YoY
23.65M
23.65M – 23.65M
+24.1% YoY
EBITDA
-24.17M
est: -3.48M (-594.6%)
-10.57M
est: -1.65M (-542.2%)
-6.73M
est.
-6.99M
est.
-8.12M
-8.12M – -8.12M
-16.2% YoY
-10.08M
-10.08M – -10.08M
-24.1% YoY
EBIT
-25.77M
est: -3.52M (-633.0%)
-11.68M
est: -1.66M (-602.3%)
-6.80M
est.
-7.06M
est.
-8.20M
-8.20M – -8.20M
-16.2% YoY
-10.18M
-10.18M – -10.18M
-24.1% YoY
Net Income
-24.36M
est: -28.35M (+14.1%)
-10.63M
est: -10.63M (+0.0%)
-1.54M
est.
-1.69M
est.
-688.7K
-712.4K – -664.9K
+59.2% YoY
23.7K
-47.5K – 95.0K
+103.4% YoY
SGA
2.68M
est: 4.03M (-33.6%)
1.41M
est: 1.91M (-26.2%)
7.80M
est.
8.09M
est.
9.40M
9.40M – 9.40M
+16.2% YoY
11.67M
11.67M – 11.67M
+24.1% YoY
EPS
-5.90
est: -5.97 (+1.1%)
-2.24
est: -2.24 (-0.1%)
-0.33
est.
-0.36
est.
-0.15
-0.15 – -0.14
+59.2% YoY
0.01
-0.01 – 0.02
+103.4% YoY

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-24.9K
OE per share TTM
-0.01
Owner's Yield
-0.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
49.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-2.1K
Shares Outstanding
4.75M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Daniel Kruse Managing Director — male
Rebecca Kruse-Rosetti ?Head of Finance — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic